Given colchicine ease of use, low cost, good safety profile, having different anti-inflammatory mechanism of action than other IL-6 blockade, and the controversy of an effective therapy for COVID-19 so far, colchicine might serve as a potential anti-inflammatory agent among patients with severe COVID-19 pneumonia. Here, IL6 is linked to COVID-19.